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SIRT1 ameliorates oxidative 
stress induced neural cell death and is 
down-regulated in Parkinson’s disease
Preeti Singh1,2, Peter S. Hanson1 and Christopher M. Morris1,2* 
Abstract 
Background:  Sirtuins (SIRTs) are  NAD+ dependent lysine deacetylases which are conserved from bacteria to humans 
and have been associated with longevity and lifespan extension. SIRT1, the best studied mammalian SIRT is involved 
in many physiological and pathological processes and changes in SIRT1 have been implicated in neurodegenerative 
disorders, with SIRT1 having a suggested protective role in Parkinson’s disease. In this study, we determined the effect 
of SIRT1 on cell survival and α-synuclein aggregate formation in SH-SY5Y cells following oxidative stress.
Results: Over-expression of SIRT1 protected SH-SY5Y cells from toxin induced cell death and the protection con-
ferred by SIRT1 was partially independent of its deacetylase activity, which was associated with the repression of 
NF-кB and cPARP expression. SIRT1 reduced the formation of α-synuclein aggregates but showed minimal co-local-
isation with α-synuclein. In post-mortem brain tissue obtained from patients with Parkinson’s disease, Parkinson’s 
disease with dementia, dementia with Lewy bodies and Alzheimer’s disease, the activity of SIRT1 was observed to be 
down-regulated.
Conclusions: These findings suggests a negative effect of oxidative stress in neurodegenerative disorders and pos-
sibly explain the reduced activity of SIRT1 in neurodegenerative disorders. Our study shows that SIRT1 is a pro-survival 
protein that is downregulated under cellular stress.
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Background
SIRT1 is a  NAD+ dependent class III histone deacetylase 
that shares homology with yeast silent information regu-
lator, SIR2. SIRT1 is primarily a nuclear protein that shut-
tles to the cytoplasm depending upon the cell type and 
stress [1]. SIRT1 targets histones and non-histones pro-
teins that are involved in the regulation of several physi-
ological processes including mitochondrial biogenesis, 
antioxidant defence mechanisms, DNA repair, apoptosis 
and genomic stability [2]. SIR2 promotes lifespan exten-
sion in yeast [3] and brain specific overexpression of its 
mammalian homologue, SIRT1 has been reported to 
delay ageing in SIRT1 overexpressing female and male 
transgenic mice [4]. In support of this protective effect in 
ageing, SIRT1 is also implicated in life span extension in 
mice that are either calorie restricted [5] or on standard 
diet [6]. These studies show that SIRT1 when activated or 
overexpressed in a tissue-specific manner can slow down 
ageing and enhance life span.
Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder after Alzheimer’s disease 
(AD) and the most common neurodegenerative move-
ment disorder [7, 8]. The characteristic pathological 
features of the disease are the progressive loss of dopa-
minergic neurones in the substantia nigra and the accu-
mulation of α-synuclein rich Lewy bodies and Lewy 
neurites in brain stem, spinal cord and cortical regions 
[9]. The causes of PD are still unknown, although several 
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environmental and genetic risk factors are suggested as 
being causative. Ageing is however, the largest single risk 
factor for the development and progression of neuro-
degeneration by affecting a number of key cellular pro-
cesses. At the molecular level, apoptosis, oxidative stress 
and mitochondrial dysfunction have been shown to pro-
mote neurodegeneration. SIRT1 has shown to inhibit 
apoptosis by regulating p53, reducing oxidative stress by 
regulating antioxidant defences via FOXO family mem-
bers, and regulates mitochondrial biogenesis mediated by 
PGC-1α [10]. SIRT1 also maintains genomic stability by 
modulating histone acetylation. SIRT1 has been shown to 
exert neuroprotection against oxidative stress. In models 
of PD, rotenone and  MPP+ are known to reduce SIRT1 in 
primary cultures which may imply that due to reduction 
of SIRT1, neurones have reduced ability to combat oxi-
dative stress and mitochondrial dysfunction [11]. SIRT1 
is neuroprotective by deacetylating and consequently 
activating PGC-1α and maintains mitochondrial homeo-
stasis by elevating antioxidant defences against MPTP 
mediated neurotoxicity [12].
Given the possible protective role of SIRT1 in PD, we 
evaluated the role of SIRT1 and its enzymatic activity 
in oxidative stress mediated cell death and also charac-
terised the involvement of SIRT1 in PD. The effects of 
over-expression and deacetylase activity of SIRT1 on 
cell survival and α-synuclein aggregate formation were 
determined in diquat or rotenone treated SH-SY5Y cells. 
Protein expression and activity of SIRT1 was also deter-
mined in post-mortem human brain tissue obtained from 
patients with PD, PD with dementia (PDD), dementia 
with Lewy bodies (DLB) and AD.
Methods
SH‑SY5Y cell culture
SH-SY5Y neuroblastoma cells were obtained from the 
European Collection of Cell Cultures (ECACC, Salisbury, 
UK) and cultured as described previously [13]. Cells were 
grown at 37 °C in a humidified atmosphere of 95% air/5% 
 CO2.
SIRT1 overexpression and toxin treatment in SH‑SY5Y cells
Wild type SIRT1 (Flag-SIRT1 was a generous gift from 
Michael Greenberg; Addgene; Plasmid number 1791) 
and catalytically inactive SIRT1H363Y (Flag-SIRT1 
H363Y; Addgene; Plasmid number 1792 from Michael 
Greenberg) plasmids [14] were obtained from Addgene 
and sub-cloned in pLenti CMV blast (a gift from Eric 
Campeau Addgene plasmid number 17486) and empty 
pLenti CMV blast wild type served as a control [15]. 
SH-SY5Y cells were seeded in 12 well plates and the 
cells were transfected with SIRT1 or SIRT1H363Y plas-
mid (1.5 µg/well) and the control group was transfected 
with empty pLenti CMV plasmids using PEI (polyethyl-
eneimine; Invitrogen) and plasmids were incubated with 
cells at 37 °C for 48 h. Stably transfected cells were also 
studied following selection of lines using 5  µg/ml Blas-
ticidin and amplification of lines. Transfected cells were 
treated with either diquat (Sigma-Aldrich, UK) dissolved 
in PBS (phosphate buffered saline; Sigma-Aldrich) or 
rotenone (Sigma-Aldrich) dissolved in DMSO (dimethyl 
sulphoxide, Sigma-Aldrich) at a final concentration of 
0.2% PBS/DMSO and incubated overnight for 20 h. Cell 
viability was determined by Alamar Blue reduction assay 
[13].
Western blotting
Following Alamar Blue fluorescence, cell lysates were 
prepared by scraping the viable cells in native lysis buffer 
(1% 10× tris buffered saline (TBS), 0.27  M Sucrose, 1% 
Triton X-100, 1× protease inhibitor cocktail). The cell 
lysates were sonicated for 20 s using a sonic probe and the 
total protein determined using Bradford Assay (modified 
from [16]). Twenty micrograms of protein in cell lysates 
were subjected to electrophoresis and were probed using 
selected antibodies in a manner as described previously 
[13] using GAPDH as a housekeeping internal loading 
control protein.
Fluorescence immunocytochemistry
SH-SY5Y cells were grown in chamber slides (BD Fal-
con, UK) and were transfected with SIRT1 plasmids and 
treated with diquat or rotenone. The cells were washed 
with PBS and slides incubated with 4% formaldehyde 
(Sigma-Aldrich) in warm 1× PBS for 15  min and then 
washed with PBS and stored until use in 10% glycerol 
(Sigma-Aldrich, UK) at 4  °C. Cells were washed and 
blocked in 1× PBS/5% goat serum/0.3% Triton X-100 
for an hour then incubated overnight at 4  °C with anti-
SIRT1 (Santa Cruz Biotechnology) and anti-phospho-
α-synuclein (Wako, Saitama, Japan) for α˗synuclein 
aggregates. Cells were washed with PBS and incubated 
with secondary antibodies (LifeSciences, Glasgow, UK) 
for 60 min protected from light. Cells were washed with 
PBS and counterstained and mounted with ProLong 
Gold Antifade Mountant with DAPI (Thermo Fisher). 
Images were acquired using a Zeiss Axioplan 2 micro-
scope (Zeiss, Oberkochen, Germany) with a 40× objec-
tive and images captured at 1024 × 1024 pixel resolution 
for analysis. Images were quantified using ImageJ (NIH, 
Bethesda, USA). Phospho-α-synuclein aggregate immu-
noreactivity was determined by using a standardised cus-
tom histogram based coloured thresholding technique 
and then subjected to analyse particles in ImageJ. The 
parameters recorded were total area and percentage area 
of staining.
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Post‑mortem tissue analysis
Brain samples were obtained from Newcastle Brain Tissue 
Resource, a Human Tissue Authority licensed tissue bank. 
Tissue was obtained at post-mortem as soon as possible 
after death and samples snap frozen and stored at −80 °C. 
Frozen tissue of the relevant region was identified and 
protein homogenates from PD, DLB, PDD, AD and con-
trol (Table  1) were prepared by homogenising approxi-
mately 250  mg of freshly thawed grey matter in 2.5  ml 
of 0.2  M triethylammonium bicarbonate containing 1× 
protease inhibitor. After addition of 10 µl of 10% SDS to 
500  µl of homogenate, samples were vortexed and then 
sonicated using a sonic probe for 15 s, followed by sonica-
tion on ice in a sonic bath for 40 min. The concentration 
of protein was determined by Bradford assay. Western 
blotting was performed as previously [13] using GAPDH 
as a housekeeping internal loading control protein.
Sirtuin activity
Brain protein homogenates were thawed and vortexed 
and sonicated as previously and samples spun down at 
100×g at 4 °C for 5 min and the protein concentration of 
supernatant was determined by Bradford assay. Fluores-
cent SIRT substrate (p53 379–382), Ac-RHKK(Ac)-AMC 
was synthesised by Cambridge Research Biolabs, UK. 
Stock peptide was prepared as a 5 mM solution in diluted 
SIRT Assay buffer (50 mM Tris–HCl, pH 8.0, containing 
137 mM sodium chloride, 2.7 mM potassium chloride, and 
1 mM magnesium chloride) and was stored at -70 °C until 
use. Total SIRT activity was determined by using 30  μg 
protein in substrate buffer containing 41.6  µM peptide, 
1 mM  NAD+ and 100 nM Trichostatin A (as an Histone 
Deacetylase inhibitor) and incubated at room temperature 
for 2 h on a shaker. After 2 h 2.5 μg/ml trypsin in 50 mM 
nicotinamide (NAM) was added to stop further deacetyla-
tion and to cleave the deacetylated product. The fluores-
cence was recorded for each well after 1  h of incubation 
of the trypsin-NAM solution in the plate reader on excita-
tion wavelength of 350–360 nm and emission wavelength 
of 450–460 nm. SIRT1 activity was determined as EX527 
(10  μM) inhibitable activity. (Please refer to Additional 
file 3: Figure S3 for sample and buffer preparation).
Statistical analyses
Statistical analysis was performed using one-way 
ANOVA within groups and two-way ANOVA within two 
groups using SPSS21 (IBM) followed by appropriate post 
hoc (Bonferroni) non-parametric testing. Error bars rep-
resent standard deviation (±SD). p < 0.05 was considered 
statistically significant. Statistical analysis of Western 
blotting data was performed in GraphPad Prism using a 
two samples t test assuming unequal variances using pro-
tein/GAPDH ratios. Statistical significance was consid-
ered as p < 0.05. The results are presented as mean ± SD.
Results
SIRT1 reduces toxin induced cell death
Exposure to environmental factors, such as rotenone and 
diquat has been shown to lead to oxidative damage in 
dopaminergic neurones leading to parkinsonian symp-
toms in animal and cellular models [17]. In diquat treated 
cells, SIRT1WT transfected cells (see Additional file  1: 
Figure S1) showed increased rates of cell survival com-
pared to control cells (20 µM or 10 µM diquat: p < 0.001) 
and SIRT1H363Y cells (20  µM diquat: p  <  0.01; 10  µM 
diquat: p  <  0.001). Interestingly, increased cell viabil-
ity was observed in SIRT1H363Y transfected cell com-
pared to control cells (20 µM or 10 µM diquat: p < 0.001) 
(Fig.  1). In cells treated with rotenone, SIRT1WT and 
SIRT1H363Y overexpression enhanced cell viability 
(rotenone 20 μM or 0.5 μM rotenone—p < 0.001) com-
pared to control cells where SIRT1WT overexpression 
was more potent in combating oxidative stress (Fig.  1). 
Similar findings to transiently transfected cells were 
found in stably transfected cells (data not shown).
SIRT1 protects SH‑SY5Y cells by reducing expression 
of NF‑кB and cleaved PARP‑1
Overexpression of SIRT1 in diquat or rotenone treated 
SH-SY5Y cells, rescued cells from oxidative stress. To test 
Table 1 Details of brain samples used for Western blot and immunohistochemistry
Case details of tissue samples used in western blot analysis and immunohistochemistry
FCX frontal cortex, TCX temporal cortex, Cb cerebellum, Pu putamen, Hp hippocampus, PMD post-mortem delay
Groups FCX TCX Cb Pu Hp Age at death (years) Tissue pH PMD (h) Gender
M F
Control (N) 11 12 12 12 8 77.5 ± 6.98 6.17 ± 0.34 19.9 ± 6.42 7 5
PD (N) 12 12 12 12 – 77.44 ± 7.03 5.85 ± 0.06 23.44 ± 9.72 8 4
PDD (N) 8 9 12 8 – 75.93 ± 5.38 6.19 ± 0.32 24.69 ± 11.38 9 3
DLB (N) 12 12 12 12 6 77.00 ± 5.35 6.32 ± 0.29 18.0 ± 8.58 9 3
AD (N) 12 12 12 – 9 80.37 ± 5.25 6.19 ± 0.33 19.84 ± 9.30 5 7
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the possible mechanism behind this protection, cells were 
probed for NF-κB. The levels of NF-κB were reduced 
by 32–35% in SIRT1WT (p  <  0.001) and by 23–24% 
in SIRT1H363Y (p  <  0.001) cells treated with 0.2% PBS 
compared with pLenti CMV transfected cells (Fig. 2). In 
diquat treated cells, the levels of NF-κB were reduced by 
50–55% in SIRT1WT (20 µM or 10 µM diquat, p < 0.001) 
cells and by 35–40% in SIRT1H363Y (20  µM or 10  µM 
diquat, p  <  0.001) when compared to 0.2% PBS treated 
control cells. On the other hand, in pLenti CMV trans-
fected cells, diquat treatment enhanced the level of 
NF-κB by ~50% (20 µM or 10 µM diquat, p < 0.001) com-
pared to 0.2% PBS treatment (Fig. 2). In rotenone treated 
cells, the levels of NF-κB in 0.2% DMSO treated cells 
were reduced by ~34 and ~25% in SIRT1WT (p < 0.001) 
and SIRT1H363Y (p  <  0.001) transfected cells, respec-
tively, compared to pLenti CMV transfected cells (Fig. 1). 
Following rotenone treatment, the levels of NF-κB were 
reduced by approximately 55% in SIRT1WT cells (20 or 
0.5 µM rotenone, p < 0.001) and by approximately 35% in 
SIRT1H363Y (20 or 0.5 µM rotenone, p < 0.001), whilst in 
pLenti CMV transfected cells the levels were elevated by 
55–60% in rotenone treated cells (20 or 0.5 µM rotenone, 
p < 0.001; Fig. 1). Following toxin treatments (diquat: 20 
or 10 µM and rotenone: 20 or 0.5 µM) in all cells the lev-
els of SIRT1 were reduced by 45–50% compared to 0.2% 
vehicle treatment (p < 0.01, Additional file 1: Figure S1). 
We also analysed the expression of active cleaved Poly 
(ADP-ribose) polymerase (PARP-1) under oxidative 
stress and observed that SIRT1 overexpression reduced 
the protein level of cPARP-1 (diquat: 20 or 10  µM and 
rotenone: 20 or 0.5 µM by 50–60%; p < 0.001) and simi-
lar result was also observed in SIRT1H363Y transfected 
cells, (diquat: 20 or 10  µM and rotenone: 20 or 0.5  µM 
by 40–45%; p < 0.001), compared to pLenti CMV trans-
fected cells (Fig. 3). Western blot analysis failed to detect 
the levels of cleaved caspase 3, a finding that has been 
observed previously [13]. 
SIRT1 shows minimal co‑localisation with α‑synuclein 
but reduces aggregate formation
SIRT1 is generally localised to the nucleus and depend-
ing upon environmental cues and cell types, and can 
translocate to the cytoplasm [1] and also to mitochondria 
[18]. Nuclear SIRT1 targets the proteins involved in DNA 
repair, antioxidant defence, genomic stability and apop-
tosis [19], whereas localisation of SIRT1 in the cytoplasm 
augments cells sensitivity to apoptosis [20]. In diquat 
or rotenone treated cells, SIRT1 was predominantly 
localised to the nucleus with lower levels of protein 
observed in the cytoplasm in pLenti CMV, SIRT1WT 
or SIRT1H363Y transfected SH-SY5Y cells (Fig.  4). 
Nuclear localisation of SIRT1 correlates with its pro-
survival activity under oxidative stress. In the nucleus, 
SIRT1 targets FOXO family members and promotes the 
expression of proteins involved in antioxidant defence 
mechanisms and simultaneously inhibits the expression 
of targets involved in promotion of apoptosis [14] and 
also enhances DNA repair [21].
Under basal conditions, we observed small punctate 
cytoplasmic accumulations of phosphor-α-synuclein 
staining which was reduced following SIRT1WT treat-
ment (p  <  0.01, Fig.  5) but not with catalytically inac-
tive SIRT1H363Y transfected cells. On treatment with 
diquat or rotenone, a significant reduction in the num-
ber of phospho-α-synuclein aggregates was observed in 
both SIRT1WT and SIRT1H363Y transfected cells com-
pared to pLenti CMV transfected cells (p < 0.001; Fig. 5). 
SIRT1 showed minimal co-localisation with phospho-α-
synuclein hence its effect on aggregate formation could 
possibly be through a positive action on ROS scavenging. 
Compared to SIRT1WT transfected cells, phospho-α-
synuclein aggregation was higher in SIRT1H363Y trans-
fected cells (p < 0.001; Fig. 5).
Fig. 1 Effect of SIRT1 and its deacetylase activity on cell viability 
of toxin treated SH-SY5Y cells. SIRT1WT and SIRT1H363Y were 
over-expressed in SH-SY5Y cells and control cells were transfected 
with empty pLenti CMV vector following which cells were treated 
with diquat (20 or 10 μM) or rotenone (20 or 0.5 μM) for 20 h and 
viability was measured by reduction of Alamar Blue. Data are 
presented as mean % control ± SD from three independent assays 
(n = 3). ***p < 0.001 and **p < 0.01 when compared to 0.2% vehicle 
(PBS/DMSO), one-way ANOVA (Bonferroni corrected), ###p < 0.001 
and ##p < 0.01 when compared to empty vector treatment and 
~~~p < 0.001 when compared to SIRT1WT, two-way ANOVA (Bonfer-
roni corrected)
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SIRT1 protein in neurodegenerative disorders
We determined SIRT1 protein and enzyme activity in 
post mortem human brain tissue in PD and other neu-
rodegenerative disorders. Two isoforms of SIRT1 pro-
tein are known (UniProt Q96EB6 (SIRT1_HUMAN), 
SIRT1FL; predicted molecular weight 80  kDa) how-
ever the observed molecular weight on Western blot is 
~120 kDa possibly due to post translational modifications 
[22] along with a shorter form, isoform 2, of approxi-
mately 75 kDa. The 120 kDa SIRT1 isoform was observed 
only in frontal cortex samples and SIRT1 isoform 2 was 
observed only in the temporal cortex samples.
In the frontal cortex samples of PD, the levels of 
120 kDa SIRT1 were reduced by 28% compared to con-
trols (p  <  0.05) whereas no significant difference was 
observed in the levels of SIRT1FL (80 kDa). In the tem-
poral cortex samples from PD cases, the levels of 80 kDa 
SIRT1FL were elevated by 15% (p  <  0.01) and 75  kDa 
isoform 2 were elevated by 36% (p  <  0.001) compared 
to controls. In the putamen or cerebellum of PD cases, 
Fig. 2 Expression of NF-κB in toxin treated SH-SY5Y. SIRT1WT and SIRT1H363Y were over-expressed in SH-SY5Y cells and control cells were 
transfected with empty vector following which cells were treated with diquat (a 20 or b 10 μM) or rotenone (c 20 or d 0.5 μM) for 20 h. Cells were 
harvested and the samples were probed for NF-κB. Data are presented as fold-untreated (+SD) from three independent assays (n = 3) with compar-
ison to GAPDH as a housekeeping control protein. ***p < 0.001 when compared to 0.2% PBS, one-way ANOVA (Bonferroni corrected), ###p < 0.001 
when compared to empty vector treatment, ~~~p < 0.001, ~~p < 0.01 and ~p < 0.05 when compared to SIRT1WT cells, two-way ANOVA (Bonferroni 
corrected). Images are representative blot of NF-κB and GAPDH
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no significant differences were observed in the levels of 
80  kDa SIRT1FL isoform when compared to control 
(Fig. 6).
In the frontal cortex of PDD, no significant differ-
ences were observed in the levels of 80  kDa SIRT1FL 
and 120kDaSIRT1 compared to control. In the temporal 
cortex of PDD, no significant difference was observed in 
the level of SIRT1FL but the level of the 75 kDa isoform 
2 was reduced by 26% compared to control (p < 0.01). In 
the putamen or cerebellum of PDD cases, no significant 
differences were observed in the levels of SIRT1 when 
compared to control (Fig. 7).
In the frontal cortex of DLB, no changes were observed 
in the levels of 120  kDaSIRT1 whereas, SIRT1FL was 
up regulated by 22% (p  <  0.05). In the temporal cortex 
of DLB, SIRT1FL was up regulated by 38% (p  <  0.001) 
whilst, no changes were observed in the levels of isoform 
2. In the putamen or hippocampus of DLB cases, no sig-
nificant difference was observed in the levels of SIRT1 
when compared to control. The expression of SIRT1 was 
up regulated by 21% (p < 0.05) in the cerebellum of DLB 
cases compared to control (Additional file 2: Figure S2).
In the frontal cortex of AD, the levels of 120 kDa SIRT1 
and 80  kDa SIRT1FL were reduced by 30% (p  <  0.01) 
and 26% (p < 0.01), respectively, when compared to con-
trol. In the temporal cortex of AD, the levels of 80kDa 
SIRT1FL were reduced by 25% (p  <  0.01), whereas, no 
significant change was observed in the level of isoform 
Fig. 3 Expression of cleaved PARP-1 in toxin treated SH-SY5Y. SIRT1WT and SIRT1H363Y were over-expressed in SH-SY5Y cells and control cells 
were transfected with empty vector following which cells were treated with diquat (a 20 or b 10 μM) or rotenone (c 20 or d 0.5 μM) for 24 h. Cells 
were harvested and the samples were probed for cPARP-1. Data are presented as fold-untreated (+SD) from three independent assays (n = 3) with 
comparison to GAPDH as a housekeeping control protein. ***p < 0.001 and **p < 0.01 when compared to 0.2% PBS, one-way ANOVA (Bonferroni 
corrected), ###p < 0.001 when compared to empty vector treatment, ~p < 0.05 when compared to SIRT1WT cells, two-way ANOVA (Bonferroni cor-
rected). Images are representative blot of cPARP1 and GAPDH
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Fig. 4 Localisation of SIRT1 and phospho-α-synuclein in toxin treated SH-SY5Y cells. Cellular distribution of SIRT1 and phospho-α-synuclein was 
determined using fluorescent immunocytochemistry. Images show α-synuclein immunostaining, SIRT1 immunostaining and all staining merged 
including DAPI in a 20 μM diquat and b 20 μM rotenone treated cells. Scale bars—white scale bar 50 μM and red scale bar 20 μM; magnification: ×40
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2. In the hippocampal and cerebellar samples of SD, the 
levels of SIRT1 were reduced by 36% (p < 0.01) and 30% 
(p < 0.001), respectively, compared to control (Additional 
file 3: Figure S3).
SIRT1 activity in neurodegenerative disorders
In the frontal cortex, measurement of total SIRT activ-
ity did not show any significant change between the dis-
ease groups and control (p > 0.05); however, compared to 
AD, the total SIRT activity was reduced in PD and DLB 
by about 20% (p < 0.01), though PDD did not show any 
significant difference. Specific SIRT1 activity was down 
regulated in PD (43%; p < 0.001), PDD (39%; p < 0.001), 
DLB (32%; p < 0.001) and AD (31%; p < 0.001) compared 
to controls (F 20.457, p < 0.001). In the temporal cortex, 
there was no significant difference in total SIRT activity 
between the disease groups and control (p > 0.05), how-
ever, compared to AD there was a significant reduction 
of 33% in total SIRT activity in PDD (p  <  0.05), though 
other groups did not show any significant change. SIRT1 
activity was reduced in PD (25%; p  <  0.01), PDD (23%; 
p < 0.05), DLB (30%; p < 0.001) and AD (22%; p < 0.05) 
compared to controls (F: 6.265, p  <  0.001) whereas no 
significant difference was seen among the disease groups 
(Fig. 8).
Discussion
Oxidative stress is an imbalance between the production 
of free radicals and antioxidant defence that leads to DNA, 
protein and lipid damage that may eventually lead to cell 
death. Oxidative stress has been suggested to play a role 
in the development and progression of neurodegenerative 
Fig. 5 Phospho-α-synuclein aggregate formation in toxin treated SH-SY5Y cells. SIRT1WT and SIRT1H363Y overexpressing SH-SY5Y cells were 
treated with toxin (20 or 10 μM diquat or 20 or 0.5 μM rotenone) and 0.2% PBS or DMSO; cells transfected with empty vector were used as a control. 
Cells were immunostained with phospho-α-synuclein. Images were captured through GFP filter under ×63 magnification. The captured images 
represent phospho-α-synuclein staining and the bar graphs represent the aggregate quantification in diquat or rotenone treated cells. Each bar rep-
resents % phospho-α-synuclein aggregates (±SD) from three independent assays (n = 3). ***p < 0.001, **p < 0.01 and *p < 0.05 when compared to 
0.2% vehicle, one-way ANOVA (Bonferroni corrected), ###p < 0.001 and ##p < 0.01 when compared to control cells, ~~~p < 0.001 and ~p < 0.05 when 
compared to SIRT1WT overexpressing cells, two-way ANOVA (Bonferroni corrected). Scale bar 20 μM
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disorders [23]. SIRT1, a  NAD+ dependent deacetylase, is 
a redox sensor and has been shown to regulate key cel-
lular processes including antioxidant defence, DNA repair 
and genomic stability [2]. In this context, we determined 
the role of SIRT1 in cell survival under oxidative stress. 
The results of our study showed increased cell survival in 
SIRT1WT and SIRT1H363Y transfected cells compared 
to control cells, nonetheless, SIRT1WT showed the high-
est rate of cell survival. In SN4741 DA neurones, Mudo 
et al. [12] reported the protective effect of SIRT1 follow-
ing MPTP treatment cells which was mediated through 
activation of PGC-1α leading to enhanced expression of 
the mitochondrial antioxidants manganese superoxide 
dismutase and Thioredoxin-2. In a recent study it was 
shown that SIRT1 alleviated rotenone induced cell death 
in SH-SY5Y cells by regulating expression of histone H3 
and p53 [24]. The present results are in line with these 
findings and establishes the pro-survival role of SIRT1 
against oxidative stress induced by diquat or rotenone in 
SH-SY5Y cells.
The findings of our study also show that the protec-
tion conferred by SIRT1 was partly independent of its 
Fig. 6 Expression of SIRT1 protein in post mortem brain in Parkinson’s Disease. The levels of SIRT1 were determined in different regions of Par-
kinson’s disease (PD) patients and compared to a control-cohort. SIRT1 band intensity was normalised with GAPDH as a housekeeping protein. 
Data are presented as fold change (±SD) with respect to control from three independent replicates of SIRT1/GAPDH. ***p < 0.001, **p < 0.01 and 
*p < 0.05 (t test). Images are representative blots of SIRT1 and GAPDH. M denotes molecular weight marker lane
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deacetylase activity as the enzymatic inactive SIRT1 
H363Y mutant also protected the cells from diquat or 
rotenone induced cell death. Similar to the findings 
of this study, Pfister et  al., showed that SIRT1WT and 
mutant forms lacking deacetylase activity (H363Y and 
H355A) protected cerebellar granule neurones from 
low-potassium induced toxicity, though in their study 
the extent of protection by mutant forms was similar to 
SIRT1WT [25]. The difference between their and our 
study could be attributed to the type of cell used and 
also the trigger causing cellular stress but does indicate 
that effects of SIRT1 can be independent of deacetylase 
activity.
The protection conferred by SIRT1 appears to be 
mediated at least in part through suppression of NF-кB 
expression, similar to the effect of SIRT1 on NF-кB 
observed by Ghosh et al., who reported that SIRT1 and 
SIRT1H363Y repressed NF-кB activity [26]. NF-кB 
transcription factors regulate inflammation and immu-
nity processes [27] and also play an important role in 
Fig. 7 Expression of SIRT1 protein in post mortem brain of Parkinson’s disease with dementia. The levels of SIRT1 were determined in different 
regions of Parkinson’s disease with dementia patients and compared to a control cohort. SIRT1 band intensity was normalised with GAPDH as 
a housekeeping protein. Data are presented as fold change (±SD) with respect to control from three independent replicates. **p < 0.01 (t test). 
Images are representative blots of SIRT1 and GAPDH. M denotes molecular weight marker lane
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cell growth and development, and apoptosis [28]. ROS 
in cells are known to activate NF-кB leading to trans-
activation of targets involved in protection against ROS 
[29] and under high oxidative stress, activation of NF-кB 
enhances cell death [30]. The results from our study show 
that SIRT1 protects cells from oxidative stress in part by 
repressing the expression of NF-кB suggesting that pos-
sibly NF-кB enhances cell death on treatment with diquat 
or rotenone.
PARP-1 (116  kDa) is a nuclear protein involved in 
detection and repair of DNA damage and is also acti-
vated during apoptosis and necrosis [13, 31] and SIRT1 
conferred protection to cells by reducing the levels of 
cleaved PARP-1 (89  kDa) following diquat or rotenone 
exposure. Rajamohan et al. [32] showed that SIRT1 dea-
cetylates PARP-1 under stress resulting in reduction of 
PARP-1 mediated cell death. They also observed that 
SIRT1 negatively regulates the PARP-1 gene promoter 
and controls the PARP-1 expression at a transcriptional 
level. The results from our study are in accord with these 
findings with reduced levels of cleaved PARP-1 protein 
in both SIRT1 WT and SIRT1H363Y cells possibly via 
a mechanism independent of the deacetylase activity of 
SIRT1 through transcriptional changes.
Lewy bodies (LBs) composed of abnormally folded 
and aggregated α-synuclein proteins, are a characteris-
tic feature of PD and other Lewy bodies disorders [33]. 
α-synuclein is a small pre-synaptic protein that undergoes 
oligomerisation and aggregation resulting in fibrillation 
and formation of LBs. Several factors trigger oligom-
erisation of α-synuclein including oxidative stress and in 
this study, we observed a low level of basal phosphor-α-
synuclein accumulation which was reduced slightly by 
SIRT1 overexpression. We also observed that under con-
ditions of oxidative stress, over-expression of SIRT1WT 
reduced the formation of phospho-α-synuclein aggregates 
and SIRT1H363Y showed a similar effect when compared 
to control cells. Interestingly, SIRT1 was not seen to co-
localise with phospho-α-synuclein suggesting that the 
effect of SIRT1 on the aggregate formation is indirect, 
independent of deacetylase activity, possibly through ele-
vation of cellular anti-oxidant defence mechanisms.
Neurodegenerative disorders typically present patho-
logically with loss of neurones in the CNS. The causes of 
Fig. 8 Total sirtuin activity and specific SIRT1 activities in frontal and temporal cortex in neurodegeneration. Total SIRT and SIRT1 activities were 
measured using a fluorometric enzymatic activity assay with specific SIRT1 inhibition in the frontal and temporal cortices of PD, PDD, DLB and AD 
patients and were compared to cohort-control group. ***p < 0.001, **p < 0.01 and *p < 0.05 when compared to control, one-way ANOVA (Bonfer-
roni corrected)
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neurodegenerative disorders are still under investigation, 
although environmental and known genetic risk factors 
are suggested to initiate these disorders, with oxidative 
stress being associated with initiation and progression of 
neurodegenerative disorders [34]. SIRT1 has been shown 
to modulate and repress the damage caused by oxidative 
stress. In this study, no major alterations were observed 
in the levels of SIRT1 protein in PD or PDD, whilst the 
levels of SIRT1 showed a slight non-significant elevation 
in DLB. However, in AD, the levels of SIRT1 protein were 
reduced in all brain regions. Pallas et  al., analysed the 
expression of SIRT1 in PD (n =  3), DLB (n =  4) in the 
frontal cortex compared to controls (n = 4) and observed 
no changes between the groups [11]. In the current study 
no major difference was seen in expression of SIRT1 
protein in PD but slightly elevated levels of the protein 
were observed in DLB. The inconsistencies between the 
previous and current studies could possibly be explained 
by group sizes with in the current study, the number of 
cases being larger. A significant reduction in the level of 
SIRT1 protein was observed in AD and this is most likely 
explained by the greater degree of cortical atrophy seen 
in AD and the loss of neuronal or synaptic SIRT1 [35]. To 
further assess the role of SIRT1, activity was measured 
and compared to control, with SIRT1 activity reduced in 
all disease groups although no significant difference was 
seen between disease groups. The lower SIRT1 activ-
ity in all disease groups correlates with possible higher 
oxidative stress, synaptic and cell loss, and neuroinflam-
mation in neurodegeneration, and also with current 
findings of reduced SIRT1 levels in SH-SY5Y cells dur-
ing oxidative stress (see Additional file 1: Figure S1). The 
differences in enzyme activity and protein expression 
may be related to the different isoforms found in brain 
tissue having different enzymatic effects with some iso-
forms being more catalytically active than others. Stud-
ies have reported that oxidative stress and inflammation 
are upregulated in neurodegenerative disorders [36, 37]. 
SIRT1 has been shown to alleviate the damage induced 
by oxidative stress and neuroinflammation. Thus, down 
regulation of SIRT1 protein and activity in disease groups 
could be associated with generalised neurodegeneration 
observed in these disorders and the associated synaptic 
and neuronal loss induced by chronic oxidative stress and 
neuroinflammation.
Conclusion
In this study, we have shown that over-expression of 
SIRT1 protected SH-SY5Y cells from diquat or rotenone 
by down-regulating NF-кB and cPARP-1 and reducing 
phospho-α-synuclein aggregates. The observed protec-
tion exerted by SIRT1 is not entirely dependent on its 
deacetylase activity as the enzymatically inactive mutant 
of SIRT1 also conferred a degree of protection to cells. 
In post-mortem human brain tissue, expression of SIRT1 
protein did not differ markedly in Lewy body disorders 
whilst reductions in SIRT1 expression was observed in 
AD, though the enzymatic activity was down-regulated 
in all groups compared to controls. Based upon these 
findings it can be concluded that SIRT1 is a pro-survival 
protein which is down-regulated under oxidative stress.
Abbreviations
SIRT1: sirtuin 1; SIR2: silent information regulator 2; NAD+: nicotinamide 
adenine dinucleotide; ROS: reactive oxygen species; PD: Parkinson’s disease; 
PDD: Parkinson’s disease with dementia; DLB: dementia with Lewy bodies; AD: 
Alzheimer’s disease; NF-κB: nuclear factor kappa-light-chain-enhancer of acti-
vated B cells; FOXO: forkhead box; PGC-1a: peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha; PBS: phosphate buffered saline; DMSO: 
dimethyl sulfoxide; TBS: tris buffered saline; PEI: polyethyleneimine; NAM: 
nicotinamide; FCX: frontal cortex; TCX: temporal cortex; Cb: cerebellum; Pu: 
putamen; Hp: hippocampus; PMD: post-mortem delay.
Authors’ contributions
All the authors took part in the design and conception of the work. PS carried 
out the cell culture studies and the majority of cellular and tissue assays, par-
ticipated in the sequence alignment and drafted the manuscript. PH carried 
out the western blot assays with PS and developed the cell and immunocyto-
chemical methods. PS, PH, and CM wrote the manuscript, and all authors read 
and approved the final manuscript.
Author details
1 Medical Toxicology Centre, and NIHR Health Protection Research Unit 
in Chemical and Radiation Threats and Hazards, Newcastle University, Wolfson 
Building, Claremont Place, Newcastle upon Tyne NE2 4AA, UK. 2 NIHR Biomedi-
cal Research Unit in Lewy Body Disorders, and Biomedical Research Centre 
in Ageing and Chronic Disease, Institute of Neuroscience, Newcastle Univer-
sity, Edwardson Building, Newcastle upon Tyne NE4 5PJ, UK. 
Additional files
Additional file 1: Figure S1. Expression of SIRT1 in toxin treated SH-
SY5Y cells. SIRT1WT and SIRT1H363Y were over-expressed in SH-SY5Y cells 
and control cells were transfected with empty vector following which 
cells were treated with diquat (20 or 10 μM) or rotenone (20 or 0.5 μM) for 
20 h. Cells were harvested and the samples were probed for SIRT1. Data 
are presented as fold- untreated (+SD) from three independent assays 
(n = 3) with comparison to GAPDH as a housekeeping control protein. 
***p < 0.001 when compared to 0.2% PBS, one-way ANOVA (Bonferroni 
corrected), ###p < 0.001 when compared to empty vector treatment, 
two-way ANOVA (Bonferroni corrected). Images are representative blot of 
SIRT1 and GAPDH.
Additional file 2: Figure S2. Expression of SIRT1 in different regions of 
DLB and control brain tissue. The levels of SIRT1 were determined in differ-
ent regions of DLB patients and were compared to a control-cohort. SIRT1 
band intensity was normalised with GAPDH. Data are presented as fold 
change (±SD) with respect to control from three independent replicates 
with comparison to GAPDH as a housekeeping control protein. **p < 0.01 
and *p < 0.05 when compared to control, t test. Images are representative 
blots of SIRT1 and GAPDH. M denotes molecular weight marker lane.
Additional file 3: Figure S3. Expression of SIRT1 in different regions of 
AD and control brain tissues. The levels of SIRT1 were determined in differ-
ent regions of AD patients and were compared to a control-cohort. SIRT1 
band intensity was normalised with GAPDH. Data are presented as fold 
change (±SD) with respect to control from three independent replicates 
with GAPDH used as an internal control housekeeping protein. **p < 0.01 
and *p < 0.05 when compared to control, t test. Images are representative 
blots of SIRT1 and GAPDH. M denotes molecular weight marker lane.
Page 13 of 13Singh et al. BMC Neurosci  (2017) 18:46 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Acknowledgements
The authors would like to thank the NIHR Biomedical Research Unit in Lewy 
Body Disorders and Biomedical Research Centre in Ageing and Chronic 
Disease for funding this project.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data and cells are available on request from the authors.
Ethics approval and consent to participate
All aspects of the study concerning the use of human tissue samples were 
approved by the UK National Research Ethics Service.
Funding
The research was funded in part by the National Institute for Health Research 
Biomedical Research Unit in Lewy Body Disorders and NIHR Biomedical 
Research Centre in ageing and Chronic Disease in partnership with The New-
castle upon Tyne Hospitals NHS Foundation Trust. The views expressed are 
those of the author(s) and not necessarily those of the National Health Service, 
the National Institutes for Health Research, or the UK Department of Health.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 26 December 2016   Accepted: 27 May 2017
References
 1. Tanno M, et al. Nucleocytoplasmic shuttling of the  NAD+-dependent 
histone deacetylase SIRT1. J Biol Chem. 2007;282(9):6823–32.
 2. Guarente L. Calorie restriction and sirtuins revisited. Genes Dev. 
2013;27(19):2072–85.
 3. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-
span extension by calorie restriction in Saccharomyces cerevisiae. Science. 
2000;289(5487):2126–8.
 4. Satoh A, et al. Sirt1 extends life span and delays aging in mice through 
the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 
2013;18(3):416–30.
 5. Mercken EM, et al. SIRT1 but not its increased expression is essential for 
lifespan extension in caloric-restricted mice. Aging Cell. 2014;13(1):193–6.
 6. Mitchell SJ, et al. The SIRT1 activator SRT1720 extends lifespan and 
improves health of mice fed a standard diet. Cell Rep. 2014;6(5):836–43.
 7. de Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet 
Neurol. 2006;5(6):525–35.
 8. Tanner CM. Epidemiology of Parkinson’s disease. Neurol Clin. 
1992;10(2):317–29.
 9. Beitz JM. Parkinson’s disease: a review. Front Biosci (Schol Ed). 2014;6:65–74.
 10. Hori YS, et al. Regulation of FOXOs and p53 by SIRT1 modulators under 
oxidative stress. PLoS ONE. 2013;8(9):e73875.
 11. Pallas M, et al. Modulation of SIRT1 expression in different neu-
rodegenerative models and human pathologies. Neuroscience. 
2008;154(4):1388–97.
 12. Mudo G, et al. Transgenic expression and activation of PGC-1α protect 
dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. 
Cell Mol Life Sci. 2012;69(7):1153–65.
 13. Nisar R, et al. Diquat causes caspase-independent cell death in SH-SY5Y 
cells by production of ROS independently of mitochondria. Arch Toxicol. 
2015;89(10):1811–25.
 14. Brunet A, et al. Stress-dependent regulation of FOXO transcription factors 
by the SIRT1 deacetylase. Science. 2004;303(5666):2011–5.
 15. Campeau E, et al. A versatile viral system for expression and depletion of 
proteins in mammalian cells. PLoS ONE. 2009;4(8):e6529.
 16. Bradford MM. A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding. 
Anal Biochem. 1976;72:248–54.
 17. Di Monte DA, Lavasani M, Manning-Bog AB. Environmental factors in 
Parkinson’s disease. Neurotoxicology. 2002;23(4–5):487–502.
 18. Aquilano K, et al. Peroxisome proliferator-activated receptor gamma 
co-activator 1α (PGC-1α) and sirtuin 1 (SIRT1) reside in mitochondria: 
possible direct function in mitochondrial biogenesis. J Biol Chem. 
2010;285(28):21590–9.
 19. Poulose N, Raju R. Sirtuin regulation in aging and injury. Biochim Biophys 
Acta. 2015;1852(11):2442–55.
 20. Jin Q, et al. Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol. 
2007;213(1):88–97.
 21. Oberdoerffer P, et al. SIRT1 redistribution on chromatin promotes 
genomic stability but alters gene expression during aging. Cell. 
2008;135(5):907–18.
 22. Lynch CJ, et al. SIRT1 undergoes alternative splicing in a novel auto-
regulatory loop with p53. PLoS ONE. 2010;5(10):e13502.
 23. Giasson BI, et al. Oxidative damage linked to neurodegeneration by 
selective α-synuclein nitration in synucleinopathy lesions. Science. 
2000;290(5493):985–9.
 24. Feng Y, et al. Rotenone affects p53 transcriptional activity and apoptosis 
via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells. J Neurochem. 
2015;134(4):668–76.
 25. Pfister JA, et al. Opposing effects of sirtuins on neuronal survival: SIRT1-
mediated neuroprotection is independent of its deacetylase activity. 
PLoS ONE. 2008;3(12):e4090.
 26. Ghosh HS, et al. Sirt1 interacts with transducin-like enhancer of split-1 
to inhibit nuclear factor kappaB-mediated transcription. Biochem J. 
2007;408(1):105–11.
 27. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcrip-
tion factors in the immune system. Annu Rev Immunol. 2009;27:693–733.
 28. Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-κB signal-
ing. Cell Res. 2011;21(1):103–15.
 29. Schmitz ML, et al. NF-κB: a multifaceted transcription factor regulated at 
several levels. ChemBioChem. 2004;5(10):1348–58.
 30. Ryan KM, et al. Role of NF-κB in p53-mediated programmed cell death. 
Nature. 2000;404(6780):892–7.
 31. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures 
of cell-death proteases in neurodegeneration. Cell Commun Signal. 
2010;8:31.
 32. Rajamohan SB, et al. SIRT1 promotes cell survival under stress by 
deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. 
Mol Cell Biol. 2009;29(15):4116–29.
 33. Spillantini MG, et al. α-Synuclein in filamentous inclusions of Lewy bodies 
from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad 
Sci USA. 1998;95(11):6469–73.
 34. Kim GH, et al. The role of oxidative stress in neurodegenerative diseases. 
Exp Neurobiol. 2015;24(4):325–40.
 35. Li S, et al. Cortical and subcortical changes in Alzheimer’s disease: 
a longitudinal and quantitative MRI study. Curr Alzheimer Res. 
2016;13(5):534–44.
 36. Gandhi S, Abramov AY. Mechanism of oxidative stress in neurodegenera-
tion. Oxid Med Cell Longev. 2012;2012:428010.
 37. Glass CK, et al. Mechanisms underlying inflammation in neurodegenera-
tion. Cell. 2010;140(6):918–34.
